Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Immunotherapies targeting surface antigens have transformed the treatment landscape of multiple myeloma (MM), with GPRC5D emerging as a promising therapeutic target. Monoallelic loss of GPRC5D is frequently observed in newly diagnosed MM patients, and the incidence of acquired GPRC5D alterations increases following exposure to GPRC5D-directed therapies.
To the Editor Chimeric antigen receptor (CAR) T-cell therapies have significantly improved outcomes in relapsed/refractory multiple myeloma (RRMM). However, concerns are emerging regarding long-term toxicities, including prolonged cytopenias and an increased risk of secondary hematologic malignancies.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
